NVO

Winners After Novo Nordisk’s Insulin Rejection

Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too. More

Little News, Little Wiggle — Monday’s IP Market Recap

A slow Monday featured a lack of economic or earnings news and led investors to mostly sit on the sidelines for the day. More

12 Intraday Movers and Shakers

Federal regulators have sent a much-hyped Novo Nordisc (NVO) drug back to the drawing board...which is great for competitors like Sanofi (SNY) More

3 Healthcare Stocks Ready for a Breather

It's the hottest sector in the S&P 500 so far this year, and that means some big-name pullbacks are likely. Here are three likely candidates. More

Sector Scan: Pharmaceutical Stocks

In the pharmaceutical sector, my scans have revealed four names to buy on strength and one stinker to avoid at all costs or sell if you own it. More

Sector Scan: Healthcare Stocks

Find out which 3 healthcare stocks you should be buying, and which 3 to cut your losses on. More

Sector Scan: Medical Stocks

This week medical stocks like Merck and Pfizer are looking healthy enough to buy or play calls on More